B. Metzler seel. Sohn & Co. AG Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• B. Metzler seel. Sohn & Co. AG initiated a position in Alnylam Pharmaceuticals during the second quarter, purchasing 10,591 shares valued at approximately $3.19 million. Institutional investors collectively own 92.97% of the company.
• Alnylam reported quarterly earnings of $1.84 per share, exceeding estimates of $1.63, while revenue rose 66.9% year over year to $1.29 billion, slightly below expectations.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $386.62, despite several recent target-price reductions.

B. Metzler seel. Sohn & Co. AG bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 10,591 shares of the biopharmaceutical company's stock, valued at approximately $3,188,000.

A number of other large investors have also added to or reduced their stakes in ALNY. Brighton Jones LLC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $243,000. Geneos Wealth Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 372.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 175 shares during the last quarter. Flow Traders U.S. LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at about $241,000. Daiwa Securities Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company's stock worth $4,220,000 after purchasing an additional 35 shares during the period. Finally, NewEdge Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 70,300.0% in the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company's stock worth $229,000 after purchasing an additional 703 shares during the period. Institutional investors own 92.97% of the company's stock.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the company's stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares in the company, valued at $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company's stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $236.22 on Friday. The business's 50-day simple moving average is $267.02 and its two-hundred day simple moving average is $297.32. Alnylam Pharmaceuticals, Inc. has a 52 week low of $197.81 and a 52 week high of $495.55. The stock has a market cap of $31.61 billion, a PE ratio of 43.91 and a beta of 0.30. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts' consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the prior year, the company posted ($0.51) earnings per share. The business's quarterly revenue was up 66.9% compared to the same quarter last year. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ALNY. Barclays dropped their price target on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an "overweight" rating on the stock in a research note on Monday, August 3rd. Wells Fargo & Company decreased their target price on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an "equal weight" rating on the stock in a report on Friday, August 14th. BMO Capital Markets began coverage on Alnylam Pharmaceuticals in a research report on Wednesday. They set an "outperform" rating and a $318.00 target price on the stock. HC Wainwright cut their price target on Alnylam Pharmaceuticals from $485.00 to $455.00 and set a "buy" rating for the company in a report on Friday, July 31st. Finally, Needham & Company LLC reduced their price target on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $386.62.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source